Data presented in our study, including two unreported patients from our medical center, support treatment of DRESS with mAbs directed toward IL-5 or IL-5R, which are already Food and Drug Administration (FDA)-approved for other eosinophilic disorders. Here, IL5 is linked to eosinophil disorder.